ImprovingAnti-CancerTherapy
By reducing skin side effects.
Lutris Pharma is a clinical-stage biopharmaceutical company developing novel topical therapies that may allow patients to stay on life-saving treatments.
A Vision for Better Cancer Care
Lutris Pharma is a clinical-stage biopharmaceutical company with a vision to improve the quality of lives and quality of treatment for cancer patients.
Skin toxicity is the most prominent adverse reaction of certain cancer drugs such as EGFR inhibitors and RAS inhibitors, often limiting how well patients can tolerate cancer treatment. Lutris Pharma is developing a novel topical gel that has the potential to significantly mitigate these side effects.
LUT014 A First-in-Class Approach
Lutris Pharma is developing LUT014, a proprietary, first-in-class, small molecule that is a topical B-RAF inhibitor for the treatment of acneiform rash that results from cancer therapy. LUT014 leverages the paradoxical effect of B-RAF inhibition to mitigate the skin toxicities of certain cancer drugs.
Why rash matters to you and your doctor
Acneiform rash happens because the anti-cancer drug that can kill cancer cells also harms skin cells called keratinocytes. These cells naturally divide quickly to replenish your skin, but the cancer treatment causes them to stop dividing and die. This causes immune cells to move into the skin, which in turn creates the rash. Maintaining the recommended course of the cancer treatment is important and so is maintaining quality of life. This is where LUT014 may help.
Partner With Us
Interested in collaboration, investment, or learning more about our clinical programs? We'd love to hear from you.
Get In Touch